Rondón LA

Language: Spanish
References: 14
Page: 245-253
PDF size: 279.03 Kb.

ABSTRACT

Since their discovery in 1852 by Sulzberger and Witten, topic steroids constitute maybe the most widely used topic therapy in dermatology for various diseases. Modifications of their basic structure have been done for obtaining greater effectivity and less side-effects, and at present there are second and third generation products. They act through their anti-inflammatory, vaso-constrictor. immuno-supressor and anti-proliferative activity.
There are several classifications according to their potency, but the most practical one is the one that divides them in 4 groups. There are several tests to classify them, but the Mckenzie-Stoughton vaso-constriction or cutaneous whitening test is the most used, Their potency depends on various factors; chemical structure, topography of the area to be treated, conditions of the skin to be treated, age of the patient, vehicle in which the drug is presented, extensión of the area to be treated.
There are several risk factors, as well as relative and absolute counterindications for its use. There are many diseases susceptible to this therapy, with different response degrees. They have both local and systemic side-effects. They are very useful, but when they are used, the risk-benefit index should always be valuated.

REFERENCES

1. Sulzberger MB, Witten VH. The effect of topically applied compound F in selected dermatoses. J Invest Dermatol 1952; 19: 101-2.

2. Allevato MA, Abbruzzese M. Corticoides tópicos –De la molécula a la acción en Temas Dermatológicos: Pautas Diagnósticas y Terapéuticas. 2005 : 77-88 Editor Antonio Rondón Lugo. Tipografía Olimpia Caracas.

3. Patricia Serrano Grau Corticoides tópicos. Actualización. Med Cutan Iber Lat Am 2006; 34: 33-8.

4. Tincopa-Wong O. Terapia tópica esteroidea en Dermatología, editor O. Tincopa-Wong 1a Ed., Lima Universidad Privada Antenor Orrego, 2011, 740-8.

5. Arndt KE, LeBoit PE, Robinson JK, Wintroub BU.: Cutaneous Medicine and Surgery. WB Saunders Company. First Edition, 1996. Chapter 9: 160-6.

6. Mori M, Pimpinelli N, Gianotti B. Topical corticosteroids and unwanted local effects: improving the benefit /risk ratio. Drug Saf 1994;10: 406-12.

7. Barnes PJ. Anti-Inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci 1998; 94: 557-72.

8. Smith EW. Do we need new and different glucocorticoids? A reappraisal of the various congeners and potencial alternatives. In Kortng HC; Maibach HI (eds): Topical glucocorticoids with increased benefit/risk ratio. Basel, Karger. Curr Probl Dermatol 1993; 21: 1-10.

9. Ballarin Milán M, Sala Fortuño. Terapéutica: el empleo racional de los glucocorticoides (I): fisiología, farmacocinética, efectos farmacológicos e interacciones. Interconsulta 1996: 10: 178-88.

10. Ponec M. Glucocorticoid receptors. In Korting HC, Maibach HI (eds): Topical glucocorticoids with increased benefit/risk ratio. Basel, Karger. Curr Probl Dermatol 1993; 21: 20-8.

11. Ballona R, Ballona C. Corticoides tópicos en pediatría: una puesta al día. Dermatol Peruana 2003; 13: 163-70.

12. McKenzie AW & Stoughton RB. Method of comparing percutaneous absortion of steroids. Arch Dermatol 1962; 6: 608-10.

13. Yohn JJ, Weston WL. Topical glucocorticoids. Curr Probl Dermatol 1990; 2: 31-63.

14. Giansante E, Pérez Alfonzo R. Esteroides Tópicos en: Dermatología práctica Ibero- Latinoamericana 1a Ed. Editores: Vicente Torres L, Francisco Camacho, Martín Mihm, Arthur Sober, Ignacio Sánchez C. Imprelibros Cali, Colombia 2005; 1740-9.